National "11th Five Year Plan" and "12th Five Year Plan" major new drug development special project

Source: on October 24, 2013, the second anniversary academic conference of Kemena achievements was successfully held in Shanghai on October 19 (last Saturday) More than 400 tumor and lung cancer experts from all over the country attended the conference The presidium of the conference included academician Sun Yan, Professor Liao Meilin, Professor Wu Yilong, Professor Shi Yuankai, Professor Zhi Xiuyi and Professor Wang Changli Main venue: the main venue of the conference is jointly hosted by Professor Shi Yuankai and Professor Wu Yilong Professor Liao Meilin, Dr Ding liming, chairman of Beida company, song Ruilin, executive chairman of China Pharmaceutical Industry Research and Development Association, and academician Sun Yan delivered speeches on behalf of the host, the organizer and the leader of the clinical project respectively Welcome the experts from afar At the same time, it reported the course and achievements of Kemena in the past two years, and expressed its gratitude for the support and love of governments at all levels, leaders, experts and scholars In his speech, song Ruilin, executive chairman, affirmed the contribution of Beida company to China's pharmaceutical industry in the past two years, and mentioned the achievements of Kemena's follow-up free drug use project He encouraged Beida to make greater achievements! The experts and leaders of the presidium of the conference attended the speech of chairman Ding liming, executive chairman song Ruilin and academician Sun Yan, and then held the launching ceremony of Kemena's two-year anniversary celebration After the launching ceremony, the academic part of the conference was introduced by Professor Shi Yuankai, Dr Wang Yinxiang, President of Beida company, and Professor Cheng Gang, Beijing Hospital of the Ministry of health To report the results of clinical research, to analyze the development prospect of tumor treatment and research from the perspective of basic research, to analyze the development direction of future tumor research and to predict the future trend of NSCLC treatment from the perspective of clinical treatment progress At the end of the first half of the academic conference, Professor Wu Yilong concluded his summary Professor Wu Yilong not only summed up the current positioning and trend of targeted therapy, but also pointed out the challenges faced and expected Kemena to be brave enough to accept the challenges Professor Shi Yuankai made a report, the launching ceremony of the second anniversary celebration, Dr Wang's speech, Professor Cheng Gang's report, and Professor Wu Yilong's Report In the second half, it was divided into three sub venues: tumor multidisciplinary, respiratory and extrathoracic According to different departments, the experts participated in the meeting conducted relevant academic discussions Professor Cheng Gang and Professor Lu u are the chairmen of the multidisciplinary branch of cancer, and Professor Bai Chunxue, Professor Han Baohui and Professor Zhou Jianying are the chairmen of the respiratory branch There are 4-5 sections in each session In addition to the keynote speech, there are case sharing, comment and hot discussion The treatment progress and controversial topics in various fields were exchanged and discussed It covers a wide range of topics and provides a high academic value Kemena is a national class 1.1 new drug independently developed by Beida Pharmaceutical Co., Ltd., which is strongly supported by the national "11th Five Year Plan" and "12th Five Year Plan" major new drug creation projects, fully reflecting that China has been in the forefront of new drug research and development in the world Kemena's great achievements in the two years since its launch indicate the recognition of Chinese oncologists for the efficacy and safety of locally developed products It is believed that this product will help more patients relieve their pain, prolong their life and improve their quality of life! Group photo of expert leaders